# Data Sheet (Cat.No.T6724)

TargetMol

## Voreloxin

### Chemical Properties



CAS No. : 175414-77-4

Formula: C18H19N5O4S

Molecular Weight: 401.44

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

### Biological Description

| | |
|---|---|
| Description | Voreloxin (SNS-595) is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity. Phase 2. |
| Targets(IC50) | Apoptosis,Topoisomerase |
| In vitro | Suprofen inactivates the diclofenac-4-hydroxylase activity of baculovirus-expressed P450 2C9 in a time- and concentration-dependent manner, which is consistent with mechanism-based inactivation. [1] Suprofen is a known generator of singlet oxygen whose participation in the reaction is supported by the effects of quenchers and scavengers. Suprofen photosensitizes the production of alkali-labile cleavage sites in DNA much more efficiently than direct strand breaks. [2] Suprofen sensitizes photo-oxidation of cholesterol, producing 7 alpha- and 7 beta-hydroperoxides but not 5 alpha-hydroperoxide of cholesterol. Suprofen-sensitized photo-oxidation of membrane lipids of liposomes increases leakage of trapped glucose, suggesting photosensitized destabilization of the membrane structure. [3] Suprofen incorporation in the phosphatidylcholine (PC) evaporation vesicles (REV) membrane leads to approximately 5% increase in the encapsulation efficiency (34%) in comparison to standard REV (29%). [4] |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 20 mg/mL (49.82 mM),Heating is recommended.<br>H2O: <1 mg/mL,<br>Ethanol: <1 mg/mL,<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 2.491 mL | 12.4552 mL | 24.9103 mL |
| 5 mM | 0.4982 mL | 2.491 mL | 4.9821 mL |
| 10 mM | 0.2491 mL | 1.2455 mL | 2.491 mL |
| 50 mM | 0.0498 mL | 0.2491 mL | 0.4982 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Tsuzuki Y, et al. J Med Chem. 2004, 47(8), 2097-2109.
Yin J, Jia P, Qu X, et al.Discovery of Voreloxin as a Dual-Selective Stabilizer for c-Myc/Bcl-2 G-Quadruplexes in Leukemia.Chemical Biology & Drug Design.2024, 104(6): e70034.
Hoch U, et al. Cancer Chemother Pharmacol. 2009, 64(1), 53-65.